September 13, 2026
Stryker’s Mako robot, trauma hardware, and a fresh acquisition are doing the work the stock price has not reflected yet.
Stryker is a medical technology company trading at a significant discount to where its own analyst consensus says it belongs. That gap is the story worth watching right now.
Jon Najarian’s Shocking “Beyond SpaceX” Prediction
For 16 years, Jon Najarian was a fixture on CNBC’s Fast Money – known as the man in the red beret.
He called Apple in 2010, Tesla in 2014, and Palantir in 2020. Now that the SpaceX IPO is in the books, he’s making what he believes could be his most important call of the decade.
A shocking prediction about what comes “Beyond SpaceX.”
The roughly $100 billion device maker has seen its shares fall about 22% over the past year to around $276. Analyst price targets on SYK range from about $340 to $420 against that level. Those targets have been trimmed in recent months, yet the distance between where the stock trades and where sell-side consensus sits has actually widened, not narrowed.
What Is Dragging the Stock
CFO Preston Wells, speaking at the Wells Fargo Healthcare Conference on September 8, 2026, cited lingering effects from an earlier cyber incident, manufacturing constraints in peripheral vascular, and weaker-than-expected orthopedic demand, especially in hips. Peripheral vascular supply issues are expected to drag growth by 70 to 80 basis points in Q2, Q3, and likely into Q4.
Hips were hit harder than knees in the second and third quarters, with Europe showing the most weakness, where public health funding constraints, defense spending competition, and war-related effects have kept demand under pressure. None of that is a permanent problem. All of it is creating a temporary valuation situation.
After “33X” call, Hall of Fame Trader Jon Najarian reveals NEW Tesla prediction…
Jon Najarian put his neck out on national TV for Tesla in 2014… Before Tesla stock flew to peak gains of 3,392% today! But this “33X” call on Tesla might pale in comparison to Jon’s newest prediction about Elon Musk… That a potential $44 TRILLION plan could be coming next.
What Is Actually Working
Stryker delivered 9% organic sales growth in Q2 2026, with robust demand for capital products, an elevated backlog, and its best ever second quarter for Mako installations, indicating strong future revenue potential. Adjusted EPS grew 17.9% year over year, driven by improved gross margins and operational recovery from the cybersecurity incident.
Capital equipment and trauma and extremities are performing strongly and helping offset weakness elsewhere. Trauma and extremities posted 11.9% total growth in Q2, per Stryker’s 10-Q filing. That is not a business in distress. It is a business with one segment running below its potential while others accelerate.
New product launches including Mako RPS, Triathlon Gold, and Incompass Total Ankle are generating strong customer interest. The company is also acquiring ZuriMED to enhance its shoulder offering, which could provide additional long-term upside.
He’s been right about Elon Musk every step of the way…
I’ve been ahead of the crowd on Elon Musk, every step of the way.
After the so-called experts said Tesla was going bankrupt, I doubled down.
And the stock is up 1,510% since.
SI was one of the first to correctly predict the SpaceX IPO.
And I’ve visited Musk’s facilities across the country.
So I’m uniquely qualified to give this live demonstration of Musk’s new 70x AI agent.
The Structural Case Stays Intact
Demand for joint replacement procedures is unabated: every day, more than 10,000 people in the U.S. are turning 65. That demographic pipeline does not reverse. Surgeons delayed procedures during the summer seasonality window, but management expects seasonal improvement in September.
Stryker maintained its full-year 2026 guidance of 8.3% to 9.3% organic net sales growth and adjusted EPS of $14.95 to $15.10. Earnings are forecast to grow 16% per annum over the next three years. At $270, the stock is pricing in significantly less than that.
What Traders Watch
- Peripheral vascular recovery cadence: Management guided a steady ramp through Q3 and Q4. Any acceleration brings the full-year target back into sharper focus.
- Mako installations: Management remains confident in the longer-term outlook, especially for Mako and Mako RPS. Each installed system creates a recurring consumables and instrument stream that does not show up in headline implant numbers.
- Europe stabilization: A turn in hip volume from European markets would close the gap between reported growth and the guidance midpoint faster than most models assume.
The bull case on SYK does not require anything heroic. It requires peripheral vascular supply normalization, a seasonal uptick in orthopedic procedures, and Mako continuing to set installation records. Two of those three are already in motion.
